The Comparative Effectiveness of Potent P2Y12 Inhibitors Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing PCI: National Registry Data
Journal of Clinical Medicine · 30.10.2024 · 13 (21) · 6536
DOI: 10.3390/jcm13216536 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.10.2024. Verfasst von Réka Aliz Lukács und 4 weiteren Autor:innen. Beteiligte Einrichtung: Heart Institute, Medical School, University of Pécs, 7622 Pécs, Hungary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dual antiplatelet therapy (DAPT), which is essential in AMI management, combines aspirin with a P2Y12 receptor antagonist. This study compared the effectiveness of potent P2Y12 inhibitors versus clopidogrel in AMI patients treated with percutaneous coronary intervention (PCI).
Methods
65,986 AMI patients included in a nationwide prospective registry who underwent PCI and received DAPT were studied. In total, 9,014 patients received potent P2Y12 inhibitors, and 56,074 received clopidogrel. This study focused on mortality, recurrent myocardial infarction, stroke, repeat revascularization, and major adverse cardiovascular events (MACE) over seven years. The analysis utilized unadjusted models and inverse probability of treatment weighting (IPTW) to compare prognosis, and decision curve analyses were constructed to aid clinical decision making.
Results
Potent P2Y12 inhibitors significantly reduced mortality risk (unadjusted hazard ratio (HR): 0.58; IPTW HR: 0.68) and MACE (unadjusted HR: 0.66; IPTW HR: 0.78). Diabetic patients showed greater benefits (HR:0.45). In patients at high bleeding risk, the mortality rate was 13% (HR: 0.87, p = 0.08). For patients aged 75–79, the HR for mortality was 0.82, whereas for those aged >80 years, it was 0.79, indicating significant mortality risk reduction. Similar trends were observed for MACE.
Conclusion
This study demonstrated that potent P2Y12 inhibitors are more effective than clopidogrel in reducing mortality and MACE in patients with AMI and underscored their potential role in improving outcomes across diverse patient subgroups. The trend was consistent even during the COVID-19 pandemic. These findings highlight the need for personalized DAPT strategies, particularly for high-bleeding-risk patients, and challenge current guidelines favoring clopidogrel use in older patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Heart Institute, Medical School, University of Pécs, 7622 Pécs, Hungary.
- Hungarian Myocardial Infarction Registry, Gottsegen National Cardiovascular Center, 1096 Budapest, Hungary.
ORCID-Profile: András Jánosi
Zitieren
APA
Lukács, R. A., Tornyos, D., Kupó, P., Jánosi, A., & Komócsi, A. (2024). The Comparative Effectiveness of Potent P2Y12 Inhibitors Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing PCI: National Registry Data. Journal of Clinical Medicine, 13(21), 6536. https://doi.org/10.3390/jcm13216536
Vancouver
Lukács RA, Tornyos D, Kupó P, Jánosi A, Komócsi A. The Comparative Effectiveness of Potent P2Y12 Inhibitors Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing PCI: National Registry Data. Journal of Clinical Medicine. 2024;13(21):6536. doi:10.3390/jcm13216536
BibTeX
@article{Lukcs2024,
author = {Lukács, Réka Aliz and Tornyos, Dániel and Kupó, Péter and Jánosi, András and Komócsi, András},
title = {The Comparative Effectiveness of Potent P2Y12 Inhibitors Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing PCI: National Registry Data},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {21},
pages = {6536},
doi = {10.3390/jcm13216536}
}
EUVIMED